Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment | Zendy

Ernane Souza | Zendy; Ryan L. Crass | Zendy; Jeremy Felton | Zendy; Kengo Hanaya | Zendy; Manjunath P. Pai | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment

Author(s) -

Ernane Souza,

Ryan L. Crass,

Jeremy Felton,

Kengo Hanaya,

Manjunath P. Pai

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00027-20

Subject(s) - linezolid , metabolite , medicine , renal function , pharmacology , gastroenterology , biology , staphylococcus aureus , bacteria , vancomycin , genetics

In patients with renal impairment ( n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations ( r 2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research